$179 Million is the total value of Sio Capital Management, LLC's 46 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 71.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LLY | Sell | ELI LILLY AND CO | $4,860,000 | -1.4% | 57,786 | -13.8% | 2.72% | -5.5% |
| CAH | Sell | CARDINAL HEALTH INC | $4,726,000 | -4.7% | 57,950 | -15.9% | 2.64% | -8.6% |
| AAAP | Sell | ADVANCED ACCELERATOR APPLICATIONS SAsponsored ads | $4,326,000 | +5.4% | 108,523 | -29.2% | 2.42% | +1.1% |
| ADMP | Sell | ADAMIS PHARMACEUTICALS CORP | $3,752,000 | +13.3% | 882,862 | -16.0% | 2.10% | +8.6% |
| BSX | Sell | BOSTON SCIENTIFIC CORP | $2,238,000 | -8.8% | 90,000 | -20.7% | 1.25% | -12.6% |
| CCXI | Sell | CHEMOCENTRYX INC | $2,141,000 | -11.1% | 294,150 | -9.6% | 1.20% | -14.7% |
| AGLE | Sell | AEGLEA BIO THERAPEUTICS INC | $1,266,000 | +54.4% | 169,889 | -9.9% | 0.71% | +48.1% |
| CERN | Sell | CERNER CORPput | $1,177,000 | -83.3% | 20,000 | -86.6% | 0.66% | -84.0% |
| FWP | Sell | FORWARD PHARMA A/Ssponsored adr | $306,000 | -60.2% | 14,224 | -72.2% | 0.17% | -61.9% |
| BPMX | Sell | BIOPHARMX CORP | $158,000 | -63.1% | 313,717 | -72.6% | 0.09% | -64.8% |
| FLML | Exit | FLAMEL TECHNOLOGIES SAsponsored adr | $0 | – | -91,413 | -100.0% | -0.55% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INCput | $0 | – | -35,000 | -100.0% | -0.56% | – |
| ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -69,215 | -100.0% | -0.68% | – |
| ATNM | Exit | ACTINIUM PHARMACEUTICALS INC | $0 | – | -1,649,078 | -100.0% | -0.84% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -506,978 | -100.0% | -1.09% | – |
| SYK | Exit | STRYKER CORPput | $0 | – | -20,000 | -100.0% | -1.40% | – |
| AMGN | Exit | AMGEN INC | $0 | – | -16,430 | -100.0% | -1.40% | – |
| PRGO | Exit | PERRIGO COMPANY PLC | $0 | – | -29,329 | -100.0% | -1.42% | – |
| HUM | Exit | HUMANA INCput | $0 | – | -12,500 | -100.0% | -1.49% | – |
| BSX | Exit | BOSTON SCIENTIFIC CORPcall | $0 | – | -120,500 | -100.0% | -1.52% | – |
| AMGN | Exit | AMGEN INCcall | $0 | – | -20,000 | -100.0% | -1.71% | – |
| PHG | Exit | KONINKLIJKE PHILIPS NVcall | $0 | – | -100,000 | -100.0% | -1.78% | – |
| NTUS | Exit | NATUS MEDICAL INC | $0 | – | -90,865 | -100.0% | -1.84% | – |
| ACRS | Exit | ACLARIS THERAPEUTICS INC | $0 | – | -138,441 | -100.0% | -2.19% | – |
| AGN | Exit | ALLERGAN PLCput | $0 | – | -20,000 | -100.0% | -2.45% | – |
| ZTS | Exit | ZOETIS INCput | $0 | – | -80,000 | -100.0% | -2.50% | – |
| AMGN | Exit | AMGEN INCput | $0 | – | -30,000 | -100.0% | -2.56% | – |
| WBA | Exit | WALGREENS BOOTS ALLIANCE INCput | $0 | – | -57,000 | -100.0% | -2.75% | – |
| ZBH | Exit | ZIMMER BIOMET HOLDINGS INC | $0 | – | -46,723 | -100.0% | -2.81% | – |
| CAH | Exit | CARDINAL HEALTH INCput | $0 | – | -70,000 | -100.0% | -2.94% | – |
| EW | Exit | EDWARDS LIFESCIENCES CORP | $0 | – | -55,000 | -100.0% | -3.01% | – |
| HRC | Exit | HILL-ROM HOLDINGS INC | $0 | – | -106,594 | -100.0% | -3.49% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCcall | $0 | – | -170,000 | -100.0% | -3.82% | – |
| SNY | Exit | SANOFI SAput | $0 | – | -210,000 | -100.0% | -4.96% | – |
| ACAD | Exit | ACADIA PHARMACEUTICALS INCput | $0 | – | -563,200 | -100.0% | -9.48% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VIKING THERAPEUTICS INC | 24 | Q3 2023 | 3.4% |
| UNITED THERAPEUTICS ORD | 23 | Q3 2023 | 8.3% |
| CARDINAL HEALTH ORD | 20 | Q2 2022 | 7.2% |
| SANOFI SA | 19 | Q3 2022 | 9.8% |
| MEDTRONIC PLC | 18 | Q3 2023 | 5.2% |
| CATALYST BIOSCIENCES INC | 18 | Q3 2021 | 17.8% |
| PFENEX ORD | 18 | Q4 2019 | 5.9% |
| AEGLEA BIOTHERAPEUTICS INC | 18 | Q1 2023 | 1.1% |
| HCA HEALTHCARE INC | 17 | Q2 2022 | 5.5% |
| MCKESSON ORD | 17 | Q1 2022 | 6.0% |
View Sio Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Modular Medical, Inc. | February 13, 2023 | 1,091,479 | 10.0% |
| Cellectar Biosciences, Inc. | February 10, 2022 | ? | ? |
| CURIS INC | February 10, 2022 | 3,866,645 | 4.2% |
| Salarius Pharmaceuticals, Inc. | February 10, 2022 | 1,354,291 | 3.0% |
| Larimar Therapeutics, Inc. | February 16, 2021 | 188,661 | 1.2% |
| ACHIEVE LIFE SCIENCES, INC. | February 14, 2020 | ? | ? |
| Bionano Genomics, Inc | February 14, 2020 | 1,210,821 | 4.6% |
| Brickell Biotech, Inc. | February 14, 2020 | ? | ? |
| Trillium Therapeutics Inc. | February 14, 2020 | 2,751,186 | 9.8% |
| ZAFGEN, INC. | February 14, 2020 | 2,283,164 | 6.1% |
View Sio Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13G | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Sio Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.